Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | CA9 | Q16790 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | SHH | Q15465 | 3/20 | 0.35 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7789754 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL15577080 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL22759100 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL1539181 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL1539182 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL8465823 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL23438526 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL22985856 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL21983880 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 | |
| SCHEMBL5867308 | 1.00 | CA1 (0.70) | CA1CA9ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807617-B2 | Highly efficient synthesis of Z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-11-07 | — | — | US | disclosed |
| US-20210355099-A1 | HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYCLES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-11-18 | — | — | US | disclosed |
| US-11161104-B2 | Reactions of olefin derivatives in the presence of methathesis catalysts | UMICORE AG & CO. KG | 2021-11-02 | — | — | US | disclosed |
| US-11053209-B2 | Highly efficient synthesis of z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210046466-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2021-02-18 | — | — | US | disclosed |
| US-20200102285-A1 | A HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYLCES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046466-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | MDK, MTR, MUSK | CA1 3731/4885CA9 4627/4885ALDH1A1 1302/4885 |
| US-11161104-B2 | Reactions of olefin derivatives in the presence of methathesis catalysts | MDK, MTR, MUSK | CA1 3731/4885CA9 4627/4885ALDH1A1 1302/4885 |
| US-20210355099-A1 | HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYCLES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | ZKSCAN2, ZYX, SPR | CA1 1763/4885CA9 1898/4885ALDH1A1 4142/4885 |
| US-11807617-B2 | Highly efficient synthesis of Z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | ZKSCAN2, ZYX, SPR | CA1 1763/4885CA9 1898/4885ALDH1A1 4142/4885 |
| US-20200102285-A1 | A HIGHLY EFFICIENT SYNTHESIS OF Z-MACROCYLCES USING STEREORETENTIVE, RUTHENIUM-BASED METATHESIS CATALYSTS | ZKSCAN2, ZYX, ZC3H18 | CA1 1838/4885CA9 1670/4885ALDH1A1 4314/4885 |
| US-11053209-B2 | Highly efficient synthesis of z-macrocycles using stereoretentive, ruthenium-based metathesis catalysts | ZKSCAN2, ZYX, SPR | CA1 1763/4885CA9 1898/4885ALDH1A1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.